e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
147.60
+4.16 (+2.90%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
6,728,639
Open
145.10
Bid (Size)
144.50 (100)
Ask (Size)
147.60 (100)
Prev. Close
143.44
Today's Range
144.30 - 148.97
52wk Range
108.46 - 157.29
Shares Outstanding
1,253,809,440
Dividend Yield
2.22%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Worried About a Market Crash? These 3 Stocks Beat the S&P 500 in 2008 and 2022
↗
Today 11:06 EDT
These stocks can be safe-haven investments to hide out in amid market turmoil.
Via
The Motley Fool
Topics
Economy
Stocks
Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up?
↗
Today 7:35 EDT
One offers concentrated exposure to 29 pharma giants with lower volatility, while the other provides broader diversification across 251 biotech companies at a cheaper cost.
Via
The Motley Fool
Topics
ETFs
Performance
YTD
+21.4%
+21.4%
1 Month
+10.8%
+10.8%
3 Month
+13.1%
+13.1%
6 Month
-4.9%
-4.9%
1 Year
+25.1%
+25.1%
More News
Read More
Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.
↗
August 18, 2026
Via
The Motley Fool
Gilead Sciences (NASDAQ:GILD) Posts Q2 Beat but Stock Slips on Full-Year Guidance
↗
August 04, 2026
Via
Chartmill
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings?
August 14, 2026
Via
StockStory
Topics
Stocks
Global Drugmakers Earmark Billions to Ramp Up Their US Footprint
August 13, 2026
Via
Investor Brand Network
Topics
World Trade
Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript
↗
August 12, 2026
Via
The Motley Fool
Topics
Earnings
KLA, Snowflake, Airbnb And A Health Care Stock On CNBC’s ‘Final Trades’
↗
August 12, 2026
Via
Benzinga
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today
↗
August 11, 2026
Via
Benzinga
5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
August 11, 2026
Via
StockStory
Topics
Earnings
Compugen (CGEN) Q2 2026 Earnings Call Transcript
↗
August 10, 2026
Via
The Motley Fool
Topics
Earnings
3 Healthcare Stocks with Open Questions
August 10, 2026
Via
StockStory
State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026?
↗
August 05, 2026
Via
The Motley Fool
Topics
ETFs
GILD Q2 Deep Dive: Pipeline Expansion and HIV Portfolio Drive Growth Amid Margin Pressure
August 05, 2026
Via
StockStory
CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
August 04, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Q2 Earnings Call Highlights
↗
August 04, 2026
Via
MarketBeat
Topics
Earnings
Gilead Sciences (NASDAQ:GILD) Beats Expectations in Strong Q2 CY2026
August 04, 2026
Via
StockStory
Why Gilead's High-Profile HIV Drug Might Have To Play Catch-Up
↗
August 04, 2026
Via
Investor's Business Daily
SpaceX Could Swing $204 Billion After Earnings
↗
August 03, 2026
Via
Benzinga
Merck Spotlights Weekly HIV Treatment, Monthly PrEP as $5B Growth Opportunity
↗
August 03, 2026
Via
MarketBeat
Compugen Q2 Earnings Call Highlights
↗
August 03, 2026
Via
MarketBeat
Topics
Earnings
Eli Lilly Could Swing Over $76 Billion In Value After Earnings
↗
August 03, 2026
Via
Benzinga
Gilead Sciences (GILD) Q2 Earnings Report Preview: What To Look For
August 02, 2026
Via
StockStory
Topics
Artificial Intelligence
2 Large-Cap Stocks for Long-Term Investors and 1 Facing Challenges
July 31, 2026
Via
StockStory
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial
↗
July 28, 2026
Via
Benzinga
Frequently Asked Questions
Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 147.60
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 08/19/26 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 185.06B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 185B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.